COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials
Increased efficacy with longer inter-dose interval Protection of over 70% starting after a first dose First indication of reduction in disease transmission of up to 67%The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no hospitalisations, more than 22 days after the first dose. Results demonstrated vaccine efficacy of 76% (CI: 59% to